Introduction to IMI’s newest projects (3rd Call for Proposals)

Michel Goldman, MD, PhD
Executive Director

IMI Stakeholder Forum, Brussels, 30 May 2012
The Innovative Medicines Initiative: A European Response to the Innovation Challenge

M Goldman

The Innovative Medicines Initiative (IMI) was launched in 2008 as a large-scale public–private partnership between the European Commission and the European Federation of Pharmaceutical Industries and Associations (EFPIA). With a total budget of €2 billion, the IMI aims to boost the development of new medicines across Europe by implementing new collaborative endeavors between large pharmaceutical companies and other key actors in the health-care ecosystem, i.e., academic institutions, small and medium enterprises, patients, and regulatory authorities. Projects conducted by IMI consortia have already delivered meaningful results, providing proof-of-concept evidence for the efficiency of this new model of collaboration. In this article we review recent achievements of the IMI consortia and discuss the growing interest in the IMI as a best-practice model to reinvigorate drug development.
EU-AIMS: Towards new treatment for autism spectrum disorders (ASD)

Develops new tools to study the pathogenesis of ASD and test the efficacy of innovative drugs

25 Partners
- 6 EFPIA companies
- 15 Academic institutions
- 3 SMEs
- 1 charity organization

- Creates an European clinical investigator network
- Develops novel imaging biomarkers
- Establishes a biobank of DNA samples to investigate genetic predisposing factors (CNVs)
- Generates cell lines from iPS of patients

EU-AIMS at a glance

Full project title: European Autism Interventions - a Multicentre Study for Developing New Medications

Start date: 01/04/2012
Duration: 5 years
Total cost: €35.9 million

Project coordinator: F. Hoffmann-La Roche
Managing entity: King’s College London
Project website: www.eu-aims.eu
DIRECT: Towards personalised therapy of diabetes

Identifies biomarkers to predict evolution of diabetes and responses to drugs

25 Partners
- 4 EFPIA companies
- 21 Academic institutions

- Creates a large European diabetes repository of blood, urine and DNA samples
- 5000 patients with type 2 diabetes enrolled

DIRECT at a glance

Full project title: Diabetes research on patient stratification
Start date: 01/01/2012
Duration: 5 years
Total cost: €43.1 million
Project coordinator: Sanofi-Aventis Deutschland GmbH
Managing entity: University of Dundee
Project website: www.direct-diabetes.org
BIOVACSAFE: Assessing the safety of vaccines

Develops cutting edge tools to improve the testing and monitoring of vaccine safety

19 Partners
- 3 EFPIA companies
- 13 Academic institutions
- 3 SMEs

- Creates a large repository of samples to store information and explore factors involved in reactions to vaccines
PreDICT-TB: Pre-clinical approach to novel combination therapies in TB

Develop new TB drug combinations based on pre-clinical research

20 Partners
- 4 EFPIA companies
- 13 Academic institutions
- 2 SMEs
- 1 patients’ organization

- Will pool patient data from clinical trials and confront results with pre-clinical data

PREDICT-TB at a glance

Full project title: Model-based preclinical development of anti-tuberculosis drug combinations
Start date: 01/05/2012
Duration: 5 years
Total cost: €28.6 million
Project coordinator: GlaxoSmithKline
Managing entity: University of Liverpool
MIP-DILI: *Predicting liver toxicity during drug development*

Develops innovative tools to detect liver toxicity early in drug development

**26 Partners**
- 11 EFPIA companies
- 9 Academic institutions
- 6 SMEs

- Will generate tests based on iPS cells
- Will develop *in silico* models

**BIOVACSAFE at a glance**
- Full project title: Biomarkers for Enhanced Vaccine Immunosafety
- Start date: 01/03/2012
- Duration: 5 years
- Total cost: €30.2 million
- Project coordinator & managing entity: University of Surrey
- EFPIA coordinator: Novartis
- Project website: [www.biovacsafe.eu](http://www.biovacsafe.eu)
ABIRISK: Detecting immunogenicity of biopharmaceuticals

Develops cutting edge tools to assess immunogenicity of biopharmaceuticals (monoclonal antibodies, recombinant proteins…)

35 Partners
- 9 EFPIA companies
- 24 Academic institutions
- 2 SMEs

- Will pool data from industry, academia and patient registries into a single immunogenicity databank
- to better understand immunogenicity
- to better predict drug safety
THANK YOU!

www.imi.europa.eu